연구동향 분석

Can Serum be Used for Analyzing the KRASMutation Status in Patients with Advanced Colorectal Cancer?

김승태 장원진 Lihua Jin 성재숙 최윤지 김열홍 2015년

논문상세정보
인용/피인용
' Can Serum be Used for Analyzing the KRASMutation Status in Patients with Advanced Colorectal Cancer?' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • kras
  • mutation
  • neoplasms
  • serum
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,760 0

0.0%

' Can Serum be Used for Analyzing the KRASMutation Status in Patients with Advanced Colorectal Cancer?' 의 참고문헌

  • p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
    Baker SJ Cancer Res 50 : 7717 ~ 7722 [1990]
  • p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
    Baker SJ Cancer Res 50 7717-7722 [1990]
  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado RG J Clin Oncol 26 : 1626 ~ 1634 [2008]
  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado RG J Clin Oncol 26 1626-1634 [2008]
  • Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
    Bazan V Ann Oncol 13 : 1438 ~ 1446 [2002]
  • Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
    Bazan V Ann Oncol 13 1438-1446 [2002]
  • Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer
    Gonzalez-Aguilera JJ Am J Clin Oncol 27 : 39 ~ 45 [2004]
  • Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer
    Gonzalez-Aguilera JJ Am J Clin Oncol 27 39-45 [2004]
  • Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Costa DB Lung Cancer 58 : 95 ~ 103 [2007]
  • Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Costa DB Lung Cancer 58 95-103 [2007]
  • Parallel progression of primary tumours and metastases
    Klein CA Nat Rev Cancer 9 : 302 ~ 312 [2009]
  • Parallel progression of primary tumours and metastases
    Klein CA Nat Rev Cancer 9 302-312 [2009]
  • Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
    Leslie A Cancer Res 63 : 4656 ~ 4661 [2003]
  • Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas
    Leslie A Cancer Res 63 4656-4661 [2003]
  • Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    Andreyev HJ Br J Cancer 85 692-696 [2001]
  • Kirsten ras mutations in patients with colorectal cancer : the multicenter"RASCAL"study
    Andreyev HJ J Natl Cancer Inst 90 : 675 ~ 684 [1998]
  • Kirsten ras mutations in patients with colorectal cancer : the multicenter"RASCAL"study
    Andreyev HJ J Natl Cancer Inst 90 675-684 [1998]
  • Kirsten ras mutations in patients with colorectal cancer : the 'RASCAL II' study
    Andreyev HJ Br J Cancer 85 : 692 ~ 696 [2001]
  • K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
    Anker P Gastroenterology 112 : 1114 ~ 1120 [1997]
  • K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
    Anker P Gastroenterology 112 1114-1120 [1997]
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis CS N Engl J Med 359 : 1757 ~ 1765 [2008]
  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Karapetis CS N Engl J Med 359 1757-1765 [2008]
  • K-ras mutation detection in colorectal cancer using the pyrosequencing technique
    Poehlmann A Pathol Res Pract 203 : 489 ~ 497 [2007]
  • K-ras mutation detection in colorectal cancer using the pyrosequencing technique
    Poehlmann A Pathol Res Pract 203 489-497 [2007]
  • Hyperactive Ras in developmental disorders and cancer
    Schubbert S Nat Rev Cancer 7 : 295 ~ 308 [2007]
  • Hyperactive Ras in developmental disorders and cancer
    Schubbert S Nat Rev Cancer 7 295-308 [2007]
  • Global cancer statistics, 2002
    Parkin DM CA Cancer J Clin 55 : 74 ~ 108 [2005]
  • Global cancer statistics, 2002
    Parkin DM CA Cancer J Clin 55 74-108 [2005]
  • Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study
    Naguib A BMC Cancer 10 : 99 ~ [2010]
  • Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study
    Naguib A BMC Cancer 10 99- [2010]
  • Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
    Westra JL J Clin Oncol 23 : 5635 ~ 5643 [2005]
  • Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
    Westra JL J Clin Oncol 23 5635-5643 [2005]
  • Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer
    Kopreski MS Br J Cancer 76 : 1293 ~ 1299 [1997]
  • Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer
    Kopreski MS Br J Cancer 76 1293-1299 [1997]
  • Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis
    Zlobec I Int J Cancer 127 : 367 ~ 380 [2010]
  • Clinicopathological and protein characterization of BRAF-and K-RAS-mutated colorectal cancer and implications for prognosis
    Zlobec I Int J Cancer 127 367-380 [2010]
  • Circulating free DNA in plasma or serum as biomarker of carcinogenesis : practical aspects and biological significance
    Gormally E Mutat Res 635 : 105 ~ 117 [2007]
  • Circulating free DNA in plasma or serum as biomarker of carcinogenesis : practical aspects and biological significance
    Gormally E Mutat Res 635 105-117 [2007]
  • Change in HER2(ERBB2)gene status after taxane-based chemotherapy for breast cancer : polyploidization can lead to diagnostic pitfalls with potential impact for clinical management
    Valent A Cancer Genet 206 : 37 ~ 41 [2013]
  • Change in HER2(ERBB2)gene status after taxane-based chemotherapy for breast cancer : polyploidization can lead to diagnostic pitfalls with potential impact for clinical management
    Valent A Cancer Genet 206 37-41 [2013]
  • Cell-free nucleic acids as biomarkers in cancer patients
    Schwarzenbach H Nat Rev Cancer 11 : 426 ~ 437 [2011]
  • Cell-free nucleic acids as biomarkers in cancer patients
    Schwarzenbach H Nat Rev Cancer 11 426-437 [2011]
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz H N Engl J Med 350 : 2335 ~ 2342 [2004]
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz H N Engl J Med 350 2335-2342 [2004]
  • Assessment of K-ras mutation : a step toward personalized medicine for patients with colorectal cancer
    Jiang Y Cancer 115 : 3609 ~ 3617 [2009]
  • Assessment of K-ras mutation : a step toward personalized medicine for patients with colorectal cancer
    Jiang Y Cancer 115 3609-3617 [2009]
  • Analysis of circulating tumor DNA to monitor metastatic breast cancer
    Dawson SJ N Engl J Med 368 : 1199 ~ 1209 [2013]
  • Analysis of circulating tumor DNA to monitor metastatic breast cancer
    Dawson SJ N Engl J Med 368 1199-1209 [2013]
  • A genetic model for colorectal tumorigenesis
    Fearon ER Cell 61 : 759 ~ 767 [1990]
  • A genetic model for colorectal tumorigenesis
    Fearon ER Cell 61 759-767 [1990]